Administration of aspirin and rivaroxaban prevents deep vein thrombosis after total knee arthroplasty

doi:10.3969/j.issn.2095-4344.2014.13.008

Abstract

Abstract:

BACKGROUND: To date, rivaroxaban has been a clinically common anticoagulant in China; however, effective prophylaxis for venous thrombosis is associated with a markedly higher incidence of perioperative hemorrhagic complications. Although it has been reported that aspirin effectively prevents deep vein thrombosis and pulmonary embolism, the use of aspirin as a routine drug for venous thrombosis after total knee arthroplasty is still controversial.
OBJECTIVE: To compare the efficacy and safety of aspirin and rivaroxaban for prevention of deep vein thrombosis after total knee arthroplasty.
METHODS: Totally 324 patients with osteoarthritis who underwent primary unilateral total knee arthroplasty were randomly divided into three groups. Twelve hours after the surgery, three groups were given aspirin, rivaroxaban and low-molecular-weight heparin respectively. All three groups were treated for 14 days, and all of the patients were followed for 4 weeks.
RESULTS AND CONCLUSION: Compared with the low-molecular-weight heparin group, the incidence of deep vein thrombosis was lower (P < 0.05), but hidden blood loss and wound complications were more common (P < 0.05) in the rivaroxaban group. There were no significant differences between the low-molecular-weight heparin group and aspirin group in the incidence of deep vein thrombosis, hidden blood loss, wound complications or incidences of lower limb swelling and subcutaneous ecchymosis (P > 0.05). The results confirmed that rivaroxaban has a positive anticoagulation effect but leads to increases in wound complications in patients; there are no differences in efficacy and safety between aspirin and low-molecular-weight heparin, so aspirin as part of a multimodal anticoagulation therapy after total knee arthroplasty has good clinical safety and efficacy.

中国组织工程研究杂志出版内容重点：人工关节；骨植入物；脊柱；骨折；内固定；数字化骨科；组织工程

全文链接：

Key words: arthroplasty, replacement, knee, factor Xa, morpholines, thiophenes, aspirin, heparin, low-molecular-weight, venous thrombosis

CLC Number:

R318

Zou Yue, Tian Shao-qi, Wang Yuan-he, Liu Jiang-jun, Sun Kang. Administration of aspirin and rivaroxaban prevents deep vein thrombosis after total knee arthroplasty[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(13): 2012-2017.

Figures/Tables 1

References

[1] Quinlan DJ, Eikelboom JW, Dahl OE, et al. Association between asymptomatic deep vein thrombosis detected by venography and symptomatic venous thromboembolism in patients undergoing elective hip or knee surgery. J Thromb Haemost. 2007;5(7):1438-1443.

[2] Howie C, Hughes H, Watts AC. Venous thromboembolism associated with hip and knee replacement over a ten-year period: a population-based study. J Bone Joint Surg Br. 2005;87(12):1675-1680.

[3] Jameson SS, Rymaszewska M, Hui AC, et al. Wound complications following rivaroxaban administration: a multicenter comparison with low-molecular-weight heparins for thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Am. 2012;94(17):1554-1558.

[4] Gomez-Outes A, Terleira-Fernandez AI, Suarez-Gea ML, et al. Dabigatran, rivaroxaban, or apixaban versus enoxaparin for thromboprophylaxis after total hip or knee replacement: systematic review, meta-analysis, and indirect treatment comparisons. BMJ. 2012;344:e3675.

[5] Fan SD, Wang XK, Bai F, et al. The Comparative research and international analysis of the application of anticoagulant to prevent thrombosis after knee replacement surgery. Zhongguo Zuzhi Gongcheng Yanjiu. 2012;16(9): 1661-1670.

[6] Bozic KJ, Vail TP, Pekow PS, et al. Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty. 2010;25(7): 1053- 1060.

[7] Intermountain Joint Replacement Center Writing Committee. A prospective comparison of warfarin to aspirin for thromboprophylaxis in total hip and total knee arthroplasty. J Arthroplasty. 2012;27(1):1-9.

[8] China Medical Association Orthopedics Branch. Diagnosis guide of osteoarthritis (2007). Zhonghua Guanjiewaike Zazhi (Dianziban). 2007;1(4):280-283.

[9] Wang G, Zhang Y, Zhao X, et al. Impact of ivaroxaban on hidden blood loss and blood transfusion rate after primary total knee arthroplasty. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012;26(11):1306-1309.

[10] Lieberman JR. The new AAOS clinical practice guidelines on venous thromboembolic prophylaxis: how to adapt them to your practice. J Am Acad Orthop Surg. 2011;19(12): 717-721.

[11] Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl): e278S-325S.

[12] Insall JN, Dorr LD, Scott RD, et al. Rationale of the knee society clinical rating system. Clin Orthop Relat Res. 1989; (248):13-14.

[13] Bin Abd Razak HR, Tan HC. The use of pneumatic tourniquets is safe in Asians undergoing total knee arthroplasty without anticoagulation. Knee. 2013.

[14] Al-Zahid S, Davies AP. Closed suction drains, reinfusion drains or no drains in primary total knee replacement? Ann R Coll Surg Engl. 2012;94(5):347-350.

[15] Wang KB. The security and effectiveness of postoperative autotransfusion after joint replacement. Keji Xinxi. 2012; (15):450-451, 435.

[16] Zhang SX, Zhang RQ, Bao Y, et al. Functional rehabilitation care after total knee arthroplasty. Zhongguo Meirong Yixue. 2011;20(z2):215-215.

[17] Cross JB. Estimating allowable blood loss: corrected for dilution. Anesthesiology. 1983;58(3):277-280.

[18] Sehat KR, Evans R, Newman JH. How much blood is really lost in total knee arthroplasty? Correct blood loss management should take hidden loss into account. The Knee. 2000;7(3):151-155.

[19] Feldschuh J, Enson Y. Prediction of the normal blood volume: Relation of blood volume to body habitus. Circulation. 1977;56(4 Pt 1):605-612.

[20] Kilicarslan K, Yalcin N, Cicek H, et al. The effect of total synovectomy in total knee arthroplasty: a prospective randomized controlled study. Knee Surg Sports Traumatol Arthrosc. 2011;19(6):932-935.

[21] Fassiadis N. Rivaroxaban: direct factor Xa inhibition totreat acute deep vein thrombosis. Br J Hosp Med (Lond). 2011;72(9):486.

[22] Zhao X, Sun P, Zhou Y, et al. Safety, pharmacokinetics and pharmacodynamics of single/multiple doses of the oral, direct Factor Xa inhibitor rivaroxaban in healthy Chinese subjects. Br J Clin Pharmacol. 2009;68(1):77-88.

[23] Alves C, Batel-Marques F, Macedo AF. Apixaban and rivaroxaban safety after hip and knee arthroplasty: a meta-analysis. J Cardiovasc Pharmacol Ther. 2012; 17(3):266-276.

[24] Turpie AG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet. 2009;373(9676):1673-1680.

[25] Pattison E, Protheroe K, Pringle RM, et al. Reduction in haemoglobin after knee joint surgery. Ann Rheum Dis. 1973;32(6):582-584.

[26] Prasad N, Padmanabhan V, Mullaji A. Blood loss in total knee arthroplasty: an analysis of risk factors. Int Orthop. 2007;31(1):39-44.

[27] Catella-Lawson F. Vascular biology of thrombosis: platelet-vessel wall interactions and aspirin effects. Neurology. 2001;57(5 Suppl 2):S5-S7.

[28] Jameson SS, Baker PN, Charman SC, et al. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after knee replacement: a non-randomized comparison using national joint registry data. J Bone Joint Surg Br. 2012;94(7):914-918.

[29] Lotke PA, Lonner JH. The benefit of aspirin chemoprophylaxis for thromboembolism after total knee arthroplasty. Clini Orthop Relat Res. 2006;452:175-180.

[30] Brown GA. Venous thromboembolism prophylaxis after major orthopaedic surgery: a pooledanalysis of randomized controlled trials. J Arthroplasty. 2009;24(6 Suppl):77-83.

[31] Lotke PA. Aspirin prophylaxis for thromboembolic disease after total joint arthroplasty. Am J Orthop. 2007;36(9 Suppl): 14-15.